1992 Volume 83 Issue 2 Pages 183-189
We investigated the effects of intravesical instillation of BCG Tokyo 172 strain on patients with superficial bladder cancer and CIS of the bladder for tumor ablation and prophylaxis. This is the first controlled multicenter study for governmental approval of BCG Tokyo 172 strain for the treatment of superficial bladder cancer and CIS of the bladder.
One hundred-fifty-seven patients (125 with Ta or T1, and 32 with CIS) were treated by 80mg of BCG diluted in 40ml of saline, once a week for 8 weeks. The dose and interval adopted in this multicenter study was determined by the previous Phase II study conducted by the same Study Group.
Out of 125 superficial tumor Ta, T1, 83 (66.4%) showed complete disappearance of the tumor (CR) and 26 (20.8%) partial disappearance (PR), and out of 32 CIS, 27 (84.4%) showed CR and 2 (6.3%) PR. Among those patients showing CR, and PR who were treated with additional TUR-Bt, 98 patients were randomised for a controlled study of prophylactic BCG instillation. Prophylactic treatment consisted of 40mg of BCG diluted in 40ml of saline, monthly for 12 months. Forty-two patients were assigned to the treatment group, whereas the remaining 56 to the control group without any prophylactic instillation. Three cases showed tumor recurrence during the prophylactic phase. Twenty-five cases could not be treated for the whole course of phrophylactic instillation mainly due to bladder irritable symptoms.
Recurrent free curves were compared till 1050 days after the initiation of the study. However, there was no significant difference between the two groups. The result was not different when the number of instillation was taken into consideration. Thus, initial BCG therapy for tumor ablation or short term prophylactic insitillation seemed to be enough for prophylaxis of superifical bladder tumor and CIS of the bladder.
